Back to Journals » Therapeutics and Clinical Risk Management » Volume 1 » Issue 2

The controversy surrounding OxyContin abuse: issues and solutions

Authors Sujata S Jayawant, Rajesh Balkrishnan

Published 15 July 2005 Volume 2005:1(2) Pages 77—82

Sujata S Jayawant1, Rajesh Balkrishnan2

1University of Houston, Department of Clinical Sciences and Administration, Houston, TX, USA; 2Ohio State University College of Pharmacy and School of Public Health, Columbus, OH, USA

Absract: This paper overviews the controversies surrounding the abuse of prescription analgesic OxyContin® (oxycodone hydrochloride; Purdue Pharma, Stamford, CT, USA). It discusses solutions to this medication-related issue, which has been touted as reaching epidemic proportions. Relevant literature from 1990 to 2004 was identified through a MEDLINE search, and a thorough internet-based search was conducted to obtain the latest updates and government reports. OxyContin became popular as a street drug through its ability to induce a quick heroinlike euphoria. The media hype surrounding OxyContin abuse and the “black box” warning on its label may have added to the abuse and diversion. The US Food and Drug Administration took steps by writing letters to Purdue Pharma, the manufacturers of OxyContin. Purdue Pharma developed a database to identify OxyContin abusers throughout the nation and also launched campaigns to educate patients through the internet. Further suggestions to managing the abuse of OxyContin include: community pharmacists’ assessment of behavioral risk factors that could lead to patient medication abuse; medication abuse risk management courses for physicians; development of a national database linking all pharmacies specifically designed to identify abusers; and tamper-resistant prescription pads for controlled substances, which seems the most plausible and immediate solution to this problem.

Keywords: OxyContin, abuse, diversion, prescription drug abuse

Download Article [PDF] 

Readers of this article also read:

Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections

Gonzalez-Ruiz A, Seaton RA, Hamed K

Infection and Drug Resistance 2016, 9:47-58

Published Date: 15 April 2016

Nutritional management in an elderly man with esophageal and gastric necrosis after caustic soda ingestion: a case report

Rondanelli M, Peroni G, Miccono A, Guerriero F, Guido D, Perna S

Therapeutics and Clinical Risk Management 2016, 12:129-133

Published Date: 4 February 2016

Management of oxaliplatin-induced peripheral neuropathy

M Wasif Saif, John Reardon

Therapeutics and Clinical Risk Management 2005, 1:249-258

Published Date: 15 December 2005

Lifestyle changes as a treatment of gastroesophageal reflux disease: a survey of general practitioners in North Queensland, Australia

Madeleine Nowak, Petra Büttner, Beverly Raasch, Kym Daniell, Cindy McCutchan, Simone Harrison

Therapeutics and Clinical Risk Management 2005, 1:219-224

Published Date: 15 October 2005

Absence of the toll-like receptor 4 gene polymorphisms Asp299Gly and Thr399Ile in Singaporean Chinese

Xiao Hui Liang, Wai Cheung, Chew Kiat Heng, De-Yun Wang

Therapeutics and Clinical Risk Management 2005, 1:243-246

Published Date: 15 October 2005

A review of studies of adherence with antihypertensive drugs using prescription databases

Nicola Fitz-Simon, Kathleen Bennett, John Feely

Therapeutics and Clinical Risk Management 2005, 1:93-106

Published Date: 15 July 2005

Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy

Charity D Scripture, William D Figg, Alex Sparreboom

Therapeutics and Clinical Risk Management 2005, 1:107-114

Published Date: 15 July 2005